BACKGROUND AND PURPOSE: Diabetes type 2 (DM2) is associated with accelerated cognitive decline and structural brain abnormalities. Macrovascular disease has been described as a determinant for brain MRI changes in DM2, but little is known about the involvement of other DM2-related factors. METHODS: Brain MRI was performed in 1043 participants (151 DM2) with symptomatic arterial disease. Brain volumes were obtained through automated segmentation. RESULTS: Patients with arterial disease and DM2 had more global and subcortical brain atrophy (-1.20% brain/intracranial volume [95%CI -1.58 to -0.82], P<0.0005 and 0.20% ventricular/intracranial volume [0.05 to 0.34], P<0.01), larger WMH volumes (0.22 logtransformed volume [0.07 to 0.38], P<0.005), and more lacunar infarcts (OR 1.75 [1.13 to 2.69], P<0.01) than identical patients without DM2. In patients with DM2, high glucose levels (B-0.12% per mmol/L [-0.23 to -0.01], P<0.05) and diabetes duration (B-0.05% per year [-0.10 to -0.001], P<0.05) were associated with global brain atrophy. CONCLUSIONS: In patients with symptomatic arterial disease, DM2 has an added detrimental effect on the brain. In patients with DM2, hyperglycemia and diabetes duration contribute to brain atrophy.
BACKGROUND AND PURPOSE:Diabetes type 2 (DM2) is associated with accelerated cognitive decline and structural brain abnormalities. Macrovascular disease has been described as a determinant for brain MRI changes in DM2, but little is known about the involvement of other DM2-related factors. METHODS: Brain MRI was performed in 1043 participants (151 DM2) with symptomatic arterial disease. Brain volumes were obtained through automated segmentation. RESULTS:Patients with arterial disease and DM2 had more global and subcortical brain atrophy (-1.20% brain/intracranial volume [95%CI -1.58 to -0.82], P<0.0005 and 0.20% ventricular/intracranial volume [0.05 to 0.34], P<0.01), larger WMH volumes (0.22 logtransformed volume [0.07 to 0.38], P<0.005), and more lacunar infarcts (OR 1.75 [1.13 to 2.69], P<0.01) than identical patients without DM2. In patients with DM2, high glucose levels (B-0.12% per mmol/L [-0.23 to -0.01], P<0.05) and diabetes duration (B-0.05% per year [-0.10 to -0.001], P<0.05) were associated with global brain atrophy. CONCLUSIONS: In patients with symptomatic arterial disease, DM2 has an added detrimental effect on the brain. In patients with DM2, hyperglycemia and diabetes duration contribute to brain atrophy.
Authors: Elizabeth C Leritz; David H Salat; Victoria J Williams; David M Schnyer; James L Rudolph; Lewis Lipsitz; Bruce Fischl; Regina E McGlinchey; William P Milberg Journal: Neuroimage Date: 2010-10-28 Impact factor: 6.556
Authors: Amanda J Cox; Christina E Hugenschmidt; Laura M Raffield; Carl D Langefeld; Barry I Freedman; Jeff D Williamson; Fang-Chi Hsu; Donald W Bowden Journal: Neurobiol Aging Date: 2014-03-11 Impact factor: 4.673
Authors: Jeffrey Dewey; George Hana; Troy Russell; Jared Price; Daniel McCaffrey; Jaroslaw Harezlak; Ekta Sem; Joy C Anyanwu; Charles R Guttmann; Bradford Navia; Ronald Cohen; David F Tate Journal: Neuroimage Date: 2010-03-22 Impact factor: 6.556
Authors: Mark A Espeland; Michael E Miller; Joseph S Goveas; Patricia E Hogan; Laura H Coker; Jeff Williamson; Michelle Naughton; Susan M Resnick Journal: J Womens Health (Larchmt) Date: 2011-08-05 Impact factor: 2.681
Authors: Cyrus A Raji; April J Ho; Neelroop N Parikshak; James T Becker; Oscar L Lopez; Lewis H Kuller; Xue Hua; Alex D Leow; Arthur W Toga; Paul M Thompson Journal: Hum Brain Mapp Date: 2010-03 Impact factor: 5.038
Authors: R Nick Bryan; Michel Bilello; Christos Davatzikos; Ronald M Lazar; Anne Murray; Karen Horowitz; James Lovato; Michael E Miller; Jeff Williamson; Lenore J Launer Journal: Radiology Date: 2014-04-29 Impact factor: 11.105
Authors: Gul N Shah; Tulin O Price; William A Banks; Yoichi Morofuji; Andrej Kovac; Nuran Ercal; Christine M Sorenson; Eui S Shin; Nader Sheibani Journal: J Pharmacol Exp Ther Date: 2012-12-17 Impact factor: 4.030